Cost-effectiveness analysis of population-based BRCA1/2 testing, family-history-based BRCA1/2 testing, and symptom-based screening for breast and ovarian cancer in China
Incorporating family-history-based <i>BRCA1/2</i> testing into breast and ovarian cancer screening programs is cost-effective in China and warrants promotion.
Authors
- Liwei Ran (ORCID: https://orcid.org/0000-0002-4064-3030)
- Jianjun Yang (ORCID: https://orcid.org/0000-0001-6785-9627)
- Jianfei Lu (ORCID: https://orcid.org/0000-0003-0543-0109)
- Shu Wang (ORCID: https://orcid.org/0000-0001-5286-5370)
- Xiangying Feng
- Feilong Zhao
Institutions
- Capital Medical University (CN)
- Beijing Chao-Yang Hospital, Capital Medical University (CN)
- National Clinical Research Center for Digestive Diseases (CN)
- Xijing Hospital (CN)
- Tsinghua University (CN)
- Air Force Medical University (CN)
Publication Details
- Journal
- Frontiers in Public Health
- Published
- 2025-06-11
- DOI
- https://doi.org/10.3389/fpubh.2025.1479966
- Primary Topic
- BRCA gene mutations in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China